[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.176.125. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correction
November 13, 2013

Error in Figure

JAMA. 2013;310(18):1987. doi:10.1001/jama.2013.281319

In the Preliminary Communication entitled “Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial” in the August 28, 2013, issue of JAMA (2013;210[8]:804-811 doi:10.1001/JAMA.2013.109309), the figure had an error. In the right-hand box following the randomization oval, it should have read that 25 patients received “400 mg/d of sofosbuvir.” This article has been corrected online.

×